These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 27650650

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, Sariego IG, Abud-Mendoza C, Escalante WJ, Kang SW, Andersone D, Blanco F, Hong SS, Lee SH, Braun J.
    Arthritis Res Ther; 2016 Jan 20; 18():25. PubMed ID: 26795209
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.
    Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.
    BioDrugs; 2017 Aug 20; 31(4):299-316. PubMed ID: 28612180
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness.
    Cheon JH, Nah S, Kang HW, Lim YJ, Lee SH, Lee SJ, Kim SH, Jung NH, Park JE, Lee YJ, Jeon DB, Lee YM, Kim JM, Park SH.
    Adv Ther; 2021 Aug 20; 38(8):4366-4387. PubMed ID: 34250583
    [Abstract] [Full Text] [Related]

  • 10. SB5: An Adalimumab Biosimilar.
    Frampton JE.
    BioDrugs; 2018 Oct 20; 32(5):507-510. PubMed ID: 30251234
    [Abstract] [Full Text] [Related]

  • 11. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J, Kudrin A.
    Immunotherapy; 2015 Oct 20; 7(2):73-87. PubMed ID: 25713985
    [Abstract] [Full Text] [Related]

  • 12. Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease.
    Smits LJT, Grelack A, Derikx LAAP, de Jong DJ, van Esch AAJ, Boshuizen RS, Drenth JPH, Hoentjen F.
    Dig Dis Sci; 2017 Nov 20; 62(11):3117-3122. PubMed ID: 28667429
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
    Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, Baranauskaite A, Wiland P, Abud-Mendoza C, Oparanov B, Smiyan S, Kim H, Lee SJ, Kim S, Park W.
    Ann Rheum Dis; 2017 Feb 20; 76(2):355-363. PubMed ID: 27130908
    [Abstract] [Full Text] [Related]

  • 14. A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
    Kim TH, Lee SS, Park W, Song YW, Suh CH, Kim S, Lee YN, Yoo DH.
    Clin Drug Investig; 2020 Jun 20; 40(6):541-553. PubMed ID: 32328979
    [Abstract] [Full Text] [Related]

  • 15. A review of CT-P13: an infliximab biosimilar.
    McKeage K.
    BioDrugs; 2014 Jun 20; 28(3):313-21. PubMed ID: 24723086
    [Abstract] [Full Text] [Related]

  • 16. PF-06438179/GP1111: An Infliximab Biosimilar.
    Al-Salama ZT.
    BioDrugs; 2018 Dec 20; 32(6):639-642. PubMed ID: 30284704
    [Abstract] [Full Text] [Related]

  • 17. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.
    Keil R, Wasserbauer M, Zádorová Z, Hajer J, Drastich P, Wohl P, Beneš M, Bojková M, Svoboda P, Konečný M, Falt P, Vaňásek T, Pešta M, Pešek F, Bouchner L, Koželuhová J, Novotný A, Bartůsková L, Špičák J.
    Scand J Gastroenterol; 2016 Sep 20; 51(9):1062-8. PubMed ID: 27002981
    [Abstract] [Full Text] [Related]

  • 18. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
    Müller-Ladner U, Hong S, Oh C, Taylor P.
    Expert Rev Clin Immunol; 2015 Sep 20; 11 Suppl 1():S5-14. PubMed ID: 26395832
    [Abstract] [Full Text] [Related]

  • 19. Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study.
    Buer LC, Moum BA, Cvancarova M, Warren DJ, Medhus AW, Høivik ML.
    J Crohns Colitis; 2017 Mar 01; 11(3):297-304. PubMed ID: 27660339
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.